Erythropoietin ameliorates podocyte injury in advanced diabetic nephropathy in the db/db mouse

American Journal of Physiology - Renal Physiology

Volumn 305, Issue 6, 2013, Pages

  Loeffler, Ivonne ^a   Rüster, Christiane ^a   Franke, Sybille ^a   Liebisch, Marita ^a   Wolf, Gunter ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Continuous erythropoietin receptor activator; db db mouse; Diabetic nephropathy; erythropoietin; Podocytes

Indexed keywords

ALBUMIN; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; CYCLIN DEPENDENT KINASE INHIBITOR 1B; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CELL DAMAGE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; GLUCOSE BLOOD LEVEL; HEMATOPOIESIS; KIDNEY HYPERTROPHY; MOUSE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84884249802     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00643.2012     Document Type: Article

References (43)

1. Al-Khoury S, Afzali B, Shah N, Thomas S, Gusbeth-Tatomir P, Goldsmith D, Covic A. Diabetes, kidney disease and anaemia: time to tackle a troublesome triad? Int J Clin Pract 61: 281-289, 2007.
2. Alpers CE, Hudkins KL. Mouse models of diabetic nephropathy. Curr Opin Nephrol Hypertens 20: 278-284, 2011.
3. Babazono T, Hanai K, Suzuki K, Kiuchi Y, Inoue A, Tanaka M, Tanaka N, Hase M, Ishii A, Iwamoto Y. Lower haemoglobin level and subsequent decline in kidney function in type 2 diabetic adults without clinical albuminuria. Diabetologia 49: 1387-1393, 2006.
4. Baelde HJ, Eikmans M, Lappin DW, Doran PP, Hohenadel D, Brinkkoetter PT, van der Woude FJ, Waldherr R, Rabelink TJ, de Heer E, Bruijin JA. Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss. Kidney Int 71: 637-645, 2007.
5. Bennett WM. A multicenter clinical trial of epoetin beta for anemia of end-stage renal disease. J Am Soc Nephrol 1: 990-998, 1991.
6. Bondeva T, Rüster C, Franke S, Hammerschmid E, Klagsbrun M, Cohen CD, Wolf G. Advanced glycation end-products suppress neuropilin-1 expression in podocytes. Kidney Int 75: 605-616, 2009.
7. Bondeva T, Wolf G. Advanced glycation end products suppress neuropilin-1 expression in podocytes by a reduction in Sp1-dependent transcriptional activity. Am J Nephrol 30: 336-345, 2009.
8. Bosman DR, Winkler AS, Marsden JT, Macdougall IC, Watkins PJ. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care 24: 495-499, 2001.
9. Busch M, Franke S, Rüster C, Wolf G. Advanced glycation endproducts and the kidney. Eur J Clin Invest 40: 742-755, 2010.
10. Cassis P, Gallon L, Benigni A, Mister M, Pezzotta A, Solini S, Gagliardini E, Cugini D, Abbate M, Aiello S, Rocchetta F, Scudeletti P, Perico N, Noris M, Remuzzi G. Erythropoietin, but not the correction of anemia alone, protects from chronic kidney allograft injury. Kidney Int 81: 903-918, 2012.
11. Echigoya MH, Obikane K, Nakashima T, Sasaki S. Glomerular localization of erythropoietin receptor mRNA and protein in neonatal and mature mouse kidney. Nephron Exp Nephrol 100: e21-e29, 2005.
12. Elliott S, Busse L, Swift S, McCaffery I, Rossi J, Kassner P, Begley CG. Lack of expression and function of erythropoietin receptors in the kidney. Nephrol Dial Transplant 27: 2733-2745, 2012.
13. Eto N, Wada T, Inagi R, Takano H, Shimizu A, Kato H, Kurihara H, Kawachi H, Shankland SJ, Fujita T, Nangaku M. Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression. Kidney Int 72: 455-463, 2007.
14. Ghezzi P, Brines M. Erythropoietin as an antiapoptotic, tissue-protective cytokine. Cell Death Differ 11: S37-S44, 2004.
15. Gruden G, Perin PC, Camussi G. Insight on the pathogenesis of diabetic nephropathy from the study of podocyte and mesangial cell biology. Curr Diabetes Rev 1: 27-40, 2005.
16. Jefferson JA, Alpers CE, Shankland SJ. Podocyte biology for the bedside. Am J Kidney Dis 58: 835-845, 2011.
17. Logar CM, Brinkkoetter PT, Krofft RD, Pippin JW, Shankland SJ. Darbepoetin alfa protects podocytes from apoptosis in vitro and in vivo. Kidney Int 72: 489-498, 2007.
18. McGill JB, Bell DS. Anemia and the role of erythropoietin in diabetes. J Diabetes Complications 20: 262-272, 2006.
19. Meek RL, Leboeuf RC, Saha SA, Alpers CE, Hudkins KL, Cooney SK, Anderberg RJ, Tuttle KR. Glomerular cell death and inflammation with high-protein diet and diabetes. Nephrol Dial Transplant 28: 1711-1720, 2013.
20. Menne J, Park JK, Shushakova N, Mengel M, Meier M, Fliser D. The continuous erythropoietin receptor activator affects different pathways of diabetic renal injury. J Am Soc Nephrol 18: 2046-2053, 2007.
21. Müller-Krebs S, Kihm LP, Madhusudhan T, Isermann B, Reiser J, Zeier M, Schwenger V. Human RAGE antibody protects against AGEmediated podocyte dysfunction. Nephrol Dial Transplant 27: 3129-3136, 2012.
22. Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Ebihara I, Koide H. Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant 15: 1379-1383, 2000.
23. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, Coplon NS, Sun L, Meyer TW. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 99: 342-348, 1997.
24. Paschos N, Lykissas MG, Beris AE. The role of erythropoietin as an inhibitor of tissue ischemia. Int J Biol Sci 4: 161-168, 2008.
25. Ravanan R, Spiro JR, Matheison PW, Smith RN. Impact of diabetes on haemoglobin levels in renal disease. Diabetologia 50: 26-31, 2007.
26. Reiniger N, Lau K, McCalla D, Eby B, Cheng B, Lu Y, Qu W, Quadri N, Ananthakrishnan R, Furmansky M, Rosario R, Song F, Rai V, Weinberg A, Friedman R, Ramasamy R, D'Agati V, Schmidt AM. Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse. Diabetes 59: 2043-2054, 2010.
27. Rossert J, Levin A, Roger SD, Hörl WH, Fouqueray B, Gassmann-Mayer C, Frei D, McClellan WM. Effect of early correction of anemia on the progression of CKD. Am J Kidney Dis 47: 738-750, 2006.
28. Rüster C, Bondeva T, Franke S, Förster M, Wolf G. Advanced glycation end-products induce cell cycle arrest and hypertrophy in podocytes. Nephrol Dial Transplant 23: 2179-2191, 2008.
29. Rüster C, Franke S, Bondeva T, Wolf G. Erythropoietin protects podocytes from damage by advanced glycation end-products. Nephron Exp Nephrol 117: e21-e30, 2011.
30. Schiffer M, Park JK, Tossidou I, Bartels J, Shushakova N, Menne J, Fliser D. Erythropoietin prevents diabetes-induced podocyte damage. Kidney Blood Press Res 31: 411-415, 2008.
31. Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, de Zeeuw D, Ivanovich P, Levey AS, Parfrey P, Remuzzi G, Singh AK, Toto R, Huang F, Rossert J, McMurray JJ, Pfeffer MA; Trial to Reduce Cardiovascuöar Events with Aranesp Therapy (TREAT) Investigators. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 363: 1146-1155, 2010.
32. Stitt-Cavanagh E, MacLeod L, Kennedy C. The podocyte in diabetic kidney disease. Sci World J 9: 1127-1139, 2009.
33. Su J, Li SJ, Chen ZH, Zeng CH, Zhou H, Li LS, Liu ZH. Evaluation of podocyte lesion in patients with diabetic nephropathy: Wilms' tumor-1 protein used as a podocyte marker. Diabetes Res Clin Pract 87: 167-175, 2010.
34. Tanji N, Markowitz GS, Fu C, Kislinger T, Taguchi A, Pischetsrieder M, Stern D, Schmidt AM, D'Agati VD. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 11: 1656-1666, 2000.
35. Toba H, Sawai N, Morishita M, Murata S, Yoshida M, Nakashima K, Morita Y, Kobara M, Nakata T. Chronic treatment with recombinant human erythropoietin exerts renoprotective effects beyond hematopoiesis in streptozotocin-induced diabetic rat. Eur J Pharmacol 612: 106-114, 2009.
36. Turk T, Leeuwis JW, Gray J, Torti SV, Lyons KM, Nguyen TQ, Goldschmeding R. BMP signaling and podocyte markers are decreased in human diabetic nephropathy in association with CTGF overexpression. J Histochem Cytochem 57: 623-631, 2009.
37. Wendt T, Tanji N, Guo J, Hudson BI, Bierhaus A, Ramasamy R, Arnold B, Nawroth PP, Yan SF, D'Agati V, Schmidt AM. Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol 14: 1383-1395, 2003.
38. Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 54: 1626-1634, 2005.
39. Wolf G, Müller N, Hunger-Battefeld W, Kloos C, Müller UA. Hemoglobin concentrations are closely linked to renal function in patients with type 1 or 2 diabetes mellitus. Kidney Blood Press Res 31: 313-321, 2008.
40. Wolf G, Schanze A, Stahl RA, Shankland SJ, Amann K. p27Kip1 knockout mice are protected from diabetic nephropathy: evidence for p27Kip1 haplotype insufficiency. Kidney Int 68: 1583-1589, 2005.
41. Wolf G, Schroeder R, Thaiss F, Ziyadeh FN, Helmchen U, Stahl RA. Glomerular expression of p27Kip1 in diabetic db/db mouse: role of hyperglycemia. Kidney Int 53: 869-879, 1998.
42. Wolf G, Ziyadeh FN. Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. Nephron Physiol 106: p26-p31, 2007.
43. Zelmanovitz T, Gerchman F, Balthazar APS, Thomazelli FC, Matos JD, Canani LH. Diabetic nephropathy. Diabetol Metab Syndr 1: 1-17, 2009.